These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 32823961)

  • 1. Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad.
    Bleve A; Durante B; Sica A; Consonni FM
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cancer-related inflammation in the era of immunotherapy.
    Nakamura K; Smyth MJ
    Immunol Cell Biol; 2017 Apr; 95(4):325-332. PubMed ID: 27999432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
    Porta C; Sica A; Riboldi E
    FEBS J; 2018 Feb; 285(4):717-733. PubMed ID: 28985035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immune mediators in cancer: between defense and resistance.
    Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
    Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.
    Daveri E; Vergani E; Shahaj E; Bergamaschi L; La Magra S; Dosi M; Castelli C; Rodolfo M; Rivoltini L; Vallacchi V; Huber V
    Front Immunol; 2020; 11():1214. PubMed ID: 32793185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty Acid Metabolism in Myeloid-Derived Suppressor Cells and Tumor-Associated Macrophages: Key Factor in Cancer Immune Evasion.
    Siddiqui S; Glauben R
    Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting myeloid cells in the tumor sustaining microenvironment.
    Schupp J; Krebs FK; Zimmer N; Trzeciak E; Schuppan D; Tuettenberg A
    Cell Immunol; 2019 Sep; 343():103713. PubMed ID: 29129292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.
    Yan D; Adeshakin AO; Xu M; Afolabi LO; Zhang G; Chen YH; Wan X
    Front Immunol; 2019; 10():1399. PubMed ID: 31275326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDSCs in cancer: Conceiving new prognostic and therapeutic targets.
    De Sanctis F; Solito S; Ugel S; Molon B; Bronte V; Marigo I
    Biochim Biophys Acta; 2016 Jan; 1865(1):35-48. PubMed ID: 26255541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.
    Wang Y; Johnson KCC; Gatti-Mays ME; Li Z
    J Hematol Oncol; 2022 Aug; 15(1):118. PubMed ID: 36031601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
    Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
    Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
    Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
    Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer.
    Cubillos-Ruiz JR; Mohamed E; Rodriguez PC
    J Immunother Cancer; 2017; 5():5. PubMed ID: 28105371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral lipid metabolic reprogramming as a pro-tumoral regulator in the tumor milieu.
    Wang R; Hu Q; Wu Y; Guan N; Han X; Guan X
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188962. PubMed ID: 37541532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid Cell-Derived Oxidized Lipids and Regulation of the Tumor Microenvironment.
    Hicks KC; Tyurina YY; Kagan VE; Gabrilovich DI
    Cancer Res; 2022 Jan; 82(2):187-194. PubMed ID: 34764204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.